Related Experiment Video
Updated: Jul 16, 2025
09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
1.8K
SGLT2 inhibitors: an evidence-based update on cardiovascular implications
Imma Forzano1, Scott Wilson2,3, Angela Lombardi3
1International Translational Research and Medical Education (ITME) Consortium, Academic Research Unit, Department of Advanced Biomedical Sciences, "Federico II" University, Naples, Italy.
Expert Opinion on Investigational Drugs
|September 23, 2023
Summary
Sodium Glucose co-Transporter 2 (SGLT2) inhibitors, or gliflozins, are vital for diabetes treatment and show significant cardioprotective benefits, even in non-diabetic patients. Ongoing research explores their cardiovascular applications and potential off-target effects.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Sodium Glucose co-Transporter 2 (SGLT2) inhibitors, also known as gliflozins, are established treatments for diabetes mellitus.
- Recent clinical trials reveal significant cardioprotective effects of gliflozins, independent of their glucose-lowering action.
- These findings have expanded the therapeutic landscape for SGLT2 inhibitors beyond diabetes management.
Purpose of the Study:
- To summarize recent advancements in the cardiovascular applications of SGLT2 inhibitors.
- To critically evaluate the rationale and outcomes of clinical studies on gliflozins and cardiovascular disease.
- To provide an overview of ongoing trials investigating SGLT2 inhibitors in cardiovascular medicine.
Main Methods:
- Review of recent randomized clinical trials and preclinical findings concerning SGLT2 inhibitors.
- Critical examination of study rationales, methodologies, and results.
- Synthesis of current knowledge and identification of future research directions.
Main Results:
- SGLT2 inhibitors demonstrate substantial cardioprotective effects, beneficial in both diabetic and non-diabetic individuals.
- Clinical trial results have broadened the therapeutic indications for gliflozins.
- Emerging preclinical data suggest potential off-target effects that warrant further investigation.
Conclusions:
- SGLT2 inhibitors represent a significant therapeutic advance in cardiovascular medicine.
- Further research is needed to fully elucidate the cardiovascular benefits and potential risks of gliflozins.
- Ongoing trials are crucial for addressing remaining questions regarding gliflozins in cardiovascular disease.
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K
01:27Glucose Transporters
22.9K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.9K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
552
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
552
01:30Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
223
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
223
01:23Dipeptidyl Peptidase 4 Inhibitors
204
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
204